Fig. 3: Microneutralization on Day 225 by A/H5N1 virus panel and group. | Nature Communications

Fig. 3: Microneutralization on Day 225 by A/H5N1 virus panel and group.

From: An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial

Fig. 3

Sera from Day 225 (28 days post intramuscular H5N1 IIV boost) were tested by MN assay using a panel of the following viruses: A/Indonesia/5/2005 (clade 2.1), A/Vietnam/1194/2004 (clade 1), A/Anhui/1/2000 (clade 2.3.4), A/Egypt/3072/2010 (clade 2.2.1), A/Turkey/15/2006 (clade 2.2), and A/Wigeon/sc/22/2021 (clade 2.3.4.4b). Sera that were negative at the initial dilution were assigned a titer of 10. Values shown as individual results for each participant, with geometric mean titers indicated by horizontal bar with 95% confidence intervals. Samples from the placebo group were not tested against the broader panel due to low MN titers against the vaccine strains (ND, not done). Low-dose (Group A), medium-dose (Group B), and high-dose (Group C) of rH5-NE are shown in maroon, orange, and yellow. Controls, including the unadjuvanted rH5 (Group D) and placebo (Group E), are shown in cyan and gray.

Back to article page